

1 ***APOE4* and Infectious Diseases Jointly Contribute to Brain Glucose Hypometabolism, a Biomarker of**
2 **Alzheimer's Pathology: New Findings from the ADNI**

3 Aravind Lathika Rajendrakumar^{1*}, Konstantin G. Arbeev¹, Olivia Bagley¹, Matt Duan¹, Anatoliy I. Yashin¹,
4 Svetlana Ukraintseva^{1*}, for the Alzheimer's Disease Neuroimaging Initiative

5 **Author's Affiliation**

6 1. Biodemography of Aging Research Unit, Social Science Research Institute, Duke University, North
7 Carolina, United States of America

8

9 **Abstract**

10 **Background**

11 Impaired brain glucose metabolism is a preclinical feature of neurodegenerative diseases such as
12 Alzheimer's disease (AD). Infections may promote AD-related pathology. Therefore, we investigated the
13 interplay between infections and *APOE4*, a strong genetic risk factor for AD.

14 **Methods**

15 We analyzed data on 1,509 participants in the Alzheimer's Disease Neuroimaging Initiative (ADNI)
16 database using multivariate linear regression models. The outcomes were rank-
17 normalized hypometabolic convergence index (HCI), statistical regions of interest (SROI) for AD, and mild
18 cognitive impairment (MCI). Marginal mean estimates for infections, stratified by *APOE4* carrier status,
19 were then computed.

20 **Results**

21 Prior infections were associated with greater HCI [$\beta=0.15$, 95% CI: 0.03, 0.27, $p=0.01$]. The combined
22 effects of infections and *APOE4* carriers on HCI levels were significantly greater than either variable

23 alone. Among *APOE4* carriers, the estimated marginal mean was 0.62, rising to 0.77, with infections
24 ($p < 0.001$), indicating an interaction effect. Carriers with multiple infections showed greater
25 hypometabolism (higher HCl), with an estimate of 0.44 ($p = 0.01$) compared to 0.11 ($p = 0.08$) for those
26 with a single infection, revealing a dose-response relationship. The estimates for the association of
27 infections with SROI AD and SROI MCI were $\beta = -0.01$ ($p = 0.02$) and $\beta = -0.01$ ($p = 0.04$), respectively.

28 **Conclusion**

29 Our findings suggest that infections and *APOE4* jointly contribute to brain glucose hypometabolism and
30 AD pathology, supporting a “multi-hit” mechanism in AD development.

31

32 **Keywords**

33 Alzheimer’s Disease, Infections, Hypometabolic Convergence Index, Statistical Regions of Interest,
34 *APOE4*, Brain Hypometabolism

35 **1 Introduction**

36 Alzheimer's disease (AD) is a slowly developing neurodegenerative disorder that is clinically manifested
37 as dementia.¹ The current figure for the AD burden in older adults in the United States is 6.7 million, and
38 it is poised to rise to 13.8 million by 2060.² The preclinical stage of AD can last many years without
39 obvious signs of dementia.³ It is crucial to better understand this preclinical stage to develop successful
40 AD prevention.⁴ Common preclinical features of AD include toxic protein depositions, neuronal
41 apoptosis, and reduction in hippocampal volume (brain shrinkage), and brain glucose
42 hypometabolism.^{5,6} The brain glucose hypometabolism is observed long before the occurrence of overt
43 symptoms in AD and is partly due to mitochondrial dysfunction.⁷ Measuring glucose utilization in the
44 brain using positron emission tomography (PET) and 18F-fluorodeoxyglucose (FDG) allows for
45 convenient examination of hypometabolic patterns in the brain.⁸ Brain scans based on FDG PET can

46 effectively detect around 90% of AD-specific metabolic patterns, such as those in the parieto-temporal,
47 frontal, and posterior cingulate regions.⁹

48 A large genetic component drives AD (60-80%), and the entire spectrum of the disease can develop over
49 15-25 years.¹⁰ Genetic variations in the *APOE* gene could single-handedly account for a large part of the
50 risk related to AD in old age.¹¹ On the other hand, addressing modifiable risk factors could reduce or
51 delay up to 40% of dementia risk.¹² Therefore, by focusing on the modifiable risk factors, a substantial
52 part of the AD burden could be alleviated at the population level.¹³ Prevention of certain infections can
53 reduce the risk of chronic diseases, including neurological deficits.¹⁴⁻¹⁶ Accumulating evidence suggests
54 that infections could be a significant risk factor for AD that may also facilitate the development of AD
55 pathology at the preclinical stage, though the exact mechanism is unclear and might involve a direct
56 detrimental impact of infection-related factors as well as indirect effects of compromised immunity.¹⁷⁻²⁰

57 The connection between infections and AD and related pathology may also be influenced by genetic
58 factors.^{18,21,22} There are also indications that infections can contribute to brain hypometabolism, one of
59 the earliest features of AD pathology; however, research on this topic is scarce.²³ Here we explore how
60 infectious diseases may influence brain glucose metabolism in presence and absence of *APOE4*, the
61 strongest genetic risk factor for AD, in participants of the Alzheimer's Disease Neuroimaging Initiative
62 (ADNI).

63

64 **2 Materials and Methods**

65 **2.1 Study Population**

66 ADNI is a multi-center observational study that began in 2004 under the supervision of Michael W.
67 Weiner. The study recruited individuals within the 55-90 years age range, and enrollment in this cohort
68 occurs in different phases, with previous participants continuing to be in the study and new participants

69 being recruited. To compare and gain knowledge about dementia, this database maintains and updates
70 demographic, phenotypic, biomarker, and genetic data gathered from participants with normal
71 cognition, AD, and other forms of cognitive impairment. The availability of such a wide variety of
72 biomarkers provides sufficient information to learn about the evolution and pathology driving AD.²⁴

73 More details regarding the study design and objectives can be accessed here
74 (<https://adni.loni.usc.edu/study-design/>). Broadly, ADNI seeks to integrate information from
75 biomarkers, cognitive measures, and brain scans to improve AD diagnosis and treatment.²⁵ Brain scans
76 were primarily collected to learn about the structural and metabolic functions of the brain, serving as a
77 standard for differentiating the pathological changes seen in AD from those in normal aging.²⁶

78 **2.2 Predictors: Infections and *APOE4***

79 Prior infections were determined by combining information from medical history, baseline symptoms,
80 initial health assessment, and adverse effects datasets. The details of the selected subset of infections
81 included in the final dataset are illustrated in Supplementary Fig 1. Medical history information was
82 collected during the screening visit using a questionnaire. Non-harmonious disease names were
83 uniformly labeled for analytical purposes. Duplicated participant information having the same infection
84 and diagnosis date, as well as any infections lacking a diagnosis date, were subsequently excluded.
85 Covariates such as age, sex, education, race, marriage status, and *APOE4* information were retrieved
86 from the ADNIMERGE file.

87 The *APOE4* carrier status was identified from DNA extracted by Cogenics from a 3 ml aliquot of EDTA
88 blood extracted from participants during their screening visit.²⁷ Anti-diabetic medications were
89 extracted (list provided in the S2 File) using the *Anatomical Therapeutic Chemical (ATC)* classification
90 system coding (<https://www.who.int/tools/atc-ddd-toolkit/atc-classification>). Information regarding

91 smoking and alcohol usage was obtained from the medical history file. Finally, we retained infections
92 that only preceded the HCl measurements.

93 **2.3 Outcomes: Brain glucose hypometabolism, AD, and MCI**

94 Multiple PET scanners were used to capture brain images based on a standard protocol.²⁸ Measures
95 were taken to correct for the related discrepancies.²⁹ The details regarding the PET scan and related
96 protocols can be viewed elsewhere ([https://adni.loni.usc.edu/methods/pet-analysis-method/pet-](https://adni.loni.usc.edu/methods/pet-analysis-method/pet-analysis/)
97 [analysis/](https://adni.loni.usc.edu/methods/pet-analysis-method/pet-analysis/)). The generated raw PET data are centrally stored at the Laboratory of Neuroimaging (LONI) at
98 the USC Mark and Mary Stevens Neuroimaging and Informatics Institute of the University of California.³⁰

99 We retrieved the processed study outcomes from the BAIPETNMRCFDG dataset
100 (<https://adni.bitbucket.io/reference/baipetnmrc.html>). The main outcome of interest was the
101 hypometabolic convergence index (HCI), developed to reflect AD-specific hypometabolism across
102 regions of the brain by computing voxel-wise z-scores from FDG-PET brain images. Higher HCI values
103 correspond to lower levels of metabolism in the brain.³¹

104 Additionally, we examined the associations for infections with statistical regions of interest (SROI)
105 corresponding to AD and Mild Cognitive Impairment (MCI). SROI associations might provide additional
106 insights into the cerebral metabolic rate for glucose (CMRgl) decline in these brain regions, helping to
107 understand the disease-specific pathology they represent.³² The Statistical Parametric Mapping (SPM)
108 software was used to generate the HCI and SROI scores.^{32,33} The work of Landau et al. provides further
109 details on the generation and development of regions of interest in the ADNI cohort.³⁴ A decline in FDG-
110 PET Region of Interest (ROI) values suggests a pathological brain damage and may contribute to the
111 progression of dementia.³³

112 **2.4 Statistical Analysis**

113 R version 4.3.2 was used for the data linking and statistical analysis.³⁵ We analyzed the dataset with full
114 covariate and outcome information, without performing any imputations. The *ggplot2* package was
115 used to create variable distribution plots.³⁶ The leptokurtic HCl readings were normalized during the
116 *RNomni* package.³⁷ Multivariate linear regression models were conducted for all specified outcomes
117 separately. Age, education, and allele dosages of *APOE ε4* were analyzed as continuous variables.
118 Infections, AD, and diabetes medications were coded as a binary variable (yes or no). Marriage, smoking,
119 and alcohol use were coded as Ever or Never. We explored models with a full set and a reduced set of
120 covariates. The parsimonious model (the best explanatory model) was determined using the Akaike
121 Information Criterion (AIC) in the *MuMin* package.³⁸ A two-sided p-value less than 0.05 was considered
122 to support our hypothesis.

123 A *Random Forest-based* model was used to rank the significant variables according to their contributions
124 to the best model.³⁹ The effect modification for infections with HCl by *APOE4* carrier status was assessed
125 by visualizing with the *rockchalk* package.⁴⁰ Marginal mean estimates were calculated to show the
126 interaction effects for the infections across categories of *APOE4* and sex.

127 **2.5 Ethics Approval**

128 The Institutional Review Board of Duke University Health System issued approval for this study (Protocol
129 IDs Pro00109279 and Pro00105389). This publication includes only secondary analyses of existing data
130 available from ADNI, and does not include identifiable human data. Written informed consent for ADNI
131 participants was obtained by the ADNI in accordance with the local legislation and ADNI requirements.
132 ADNI studies follow Good Clinical Practices guidelines, the Declaration of Helsinki, and United States
133 regulations (U.S. 21 CFR Part 50 and Part 56).

134

135 **3 Results**

136 3.1 Participant Characteristics

137 The final sample included information on 1,509 participants after data linking (Supplementary Fig 2). As
138 shown in Table 1, the average age among participants was 73.3 years, with an average education
139 duration of 16.0 years (IQR 14.0-18.0). Over 96% of respondents reported being ever married, and 55.8%
140 were males. There was a relatively lower representation of non-white individuals, totaling 116 (7.6%) in
141 the sample. Percentage of individuals with a history of smoking and alcohol use was 27.1% and 3.3%,
142 respectively. Of these, 215 individuals accounting for 14.2% of the total sample size, reported having
143 infections. The median interval between biomarker assessment and infections was 8.4 (IQR: 3.5 - 28.3).
144 Median HCI was 12.59, and the IQR was 8.4 - 19.3.

145 Fig 1 shows the distributions of the original HCI and rank-normalized HCI and also a scatterplot of their
146 relationship. For AD and MCI participants, the mean SROI values were 1.15 and 1.03, respectively. About
147 3% of participants with diabetes were on medication, and 18.3% had an AD diagnosis. Peptic ulcer
148 disease (PUD) (n=152), urinary tract infection (UTI) (n=146), and pneumonia (n=102) were the most
149 frequent among the selected infections. Supplementary Fig 3 shows the difference in the distribution of
150 HCI values for individuals with infections, AD, and *APOE4*. The median HCI value among individuals with
151 infections was 13.64, while it was lower (12.48) for those without infections. It was also seen that the
152 HCI had a modest positive correlation with *APOE4* (Supplementary Fig 4).

153


154 Table 1. Demographic and clinical characteristics of the study population

Variable	Mean/Median /Frequency	SD/IQR	Range
Age (Years) #	73.3	7.2	55.0-91.4
Male (%)	843 (55.8%)		
Education (Years) #	16.0	14.0-18.0	4.0-20.0

Marriage Status

Ever	1455 (96.4%)		
Never	54 (3.5%)		
Race			
White	1393 (92.3%)		
Other	116 (7.6%)		
Smoking (Ever)	409 (27.1%)		
Alcohol (Ever)	50 (3.3%)		
Infections (Yes)	215 (14.2%)		
Time duration (Years) ^{#@}	8.4	3.5-28.3	0.03-86.7
HCI [#]	12.59	8.4-19.3	2.3-55.2
SROI AD	1.15	0.08	0.8-1.38
SROI MCI	1.03	0.10	0.7-1.35
APOE4[§]			
0	813 (53.8%)		
1	544 (36.0%)		
2	152 (10.0%)		
Diabetes (Yes)	43 (2.8%)		
AD	277 (18.3%)		

Note. Data are presented as mean \pm standard deviation (SD) or percentage (%) for continuous and categorical variables, respectively; [#]Variables with skewed distributions are presented as median and IQR. [§]Frequencies in the analyzed sample. [@]Time from Infection to HCI measurements.



156

157 **Fig 1.** Distribution of HCI and normalized HCI with scatterplot showing their relationship

158

159 **3.2 Association of Infections and Other Predictors with the HCI**

160 Supplementary Table 1 shows the regression estimates for all the predictors in the multivariate linear
161 regression full model for HCI outcome. Marriage status, education, smoking, alcohol, and diabetes
162 medication use were not significant predictors of HCI. Table 2 presents the results of the reduced model,
163 which best describes the model variance. AD status predicted the strongest reduction in brain
164 metabolism [$\beta = 1.04$, 95% CI 0.92-1.15, $p < 0.001$], followed by age [$\beta = 0.01$, 95% CI 0.01-0.02, $p < 0.001$]
165 and *APOE4* carrier status [$\beta = 0.32$, 0.25-0.38, $p < 0.001$]. Higher variable relevance is indicated by higher
166 values of %INCMSE and INCNodepurity (Supplementary Table 2). The regression coefficient for
167 infections was 0.15 [95% CI 0.02- 0.27, $p = 0.01$]. Males and white people were at higher risk of having
168 elevated HCI values. Smoking history was the only non-significant predictor retained in the reduced
169 model. The adjusted R-squared from the reduced model was 26.9%. Males had higher median HCI
170 values.

171 In the sex-stratified analysis evaluating the effects of infections versus non-infections, males generally
172 demonstrated relatively higher HCl values (Supplementary Table 3). The difference in normalized
173 marginal means between all groups was statistically significant ($p < 0.001$). The combined effects of
174 infections and *APOE4* carrier status on HCl levels are shown in Fig 2. This was significantly greater than
175 the effects of either variable alone. Supplementary Table 4 clarifies these results. Specifically, for
176 individuals without infections and *APOE4* carrier status, the estimated marginal mean was 0.03 ($p = 0.53$).
177 However, this increased significantly to 0.18 ($p < 0.001$) for *APOE4* non-carriers in the presence of
178 infections. Notably, among *APOE4* carriers, the estimated marginal mean was substantially higher at
179 0.62, and this value rose to 0.77 with infections ($p < 0.001$), confirming an interaction between the two
180 factors.

181 This interaction was further demonstrated in the additional analysis (Supplementary Table 5 and Fig 3),
182 indicating that carriers who experienced multiple infections exhibited greater hypometabolism. Among
183 individuals with more than one prior infection ($n = 23$), the estimate was significantly higher at 0.44
184 ($p = 0.01$) compared to those with a single infection, which was 0.11 ($p = 0.08$), revealing a dose-response
185 relationship.


186 Table 2. Regression estimates for predictors in the reduced multivariate linear regression model for HCl
187 outcome

Variables	Estimates	95% CI	P
AD (Yes)	1.04	0.92, 1.15	$< 0.001^{***}$
<i>APOE4</i>	0.32	0.25, 0.38	$< 0.001^{***}$
Age	0.01	0.01, 0.02	$< 0.001^{***}$
Infections (Yes)	0.15	0.02, 0.27	0.01*

Race (White)	0.25	0.09, 0.42	0.002**
Sex (Male)	0.17	0.09, 0.26	<0.001***
Smoking (Yes)	0.08	-0.01, 0.18	0.085

188 Note. * p<0.05; ** p<0.01; *** p<0.001.

189




190

191 **Fig 2.** Joint effect of *APOE4* and history of infections on HCl

192

193

194



195

196 **Fig 3.** Brain hypometabolism by *APOE4* carrier status and frequency of infections

197

198 3.3 Association of Infections and Other Predictors with the SROI AD

199 Supplementary Table 6 provides regression estimates for all the factors investigated for SROI AD.

200 Marriage, race, smoking, and alcohol history were not significant predictors of AD-specific

201 hypometabolism. In the reduced model shown in Table 3, AD was associated with increased region-

202 specific hypometabolism (regression coefficient: -0.08, $p < 0.001$). The use of diabetes medications was

203 associated with decreased brain metabolism (-0.03, $p = 0.02$). Similar to previous regression, an increase

204 in *APOE4* alleles was a strong risk factor for hypometabolism (-0.02, $p < 0.001$). Male gender showed

205 greater hypometabolism (-0.01, $p < 0.01$). Although education was linked to a better metabolic pattern,

206 this relationship was not profound. Age-specific decreases were not as notable as those observed in HCl

207 (-0.003, $p < 0.001$). While statistically significant, the effect estimate for previous infections was lower for
208 AD (-0.01, $p = 0.02$). These variables collectively predicted 26.8% of the variance in SROI AD.

209 Table 3. Regression estimates for predictors in the reduced multivariate linear regression model for SROI
210 AD outcome

Variables	Estimates	95% CI	P
AD (Yes)	-0.08	-0.09, -0.07	$< 0.001^{***}$
<i>APOE4</i>	-0.02	-0.03, -0.02	$< 0.001^{***}$
Age	-0.003	-0.003, -0.002	$< 0.001^{***}$
Diabetes Medication	-0.03	-0.05, -0.004	0.02^*
Education	0.001	0.00, 0.002	0.04^*
Infections (Yes)	-0.01	-0.02, -0.001	0.02^*
Sex (Male)	-0.01	-0.02, -0.003	0.00^{**}
Smoking (Yes)	-0.01	-0.02, 0.001	0.11

211 Note. * $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$.

212

213 3.4 Association of Infections and Other Predictors with the SROI MCI

214 The results of the SROI MCI regression (full model) is presented in the Supplementary Table 7. Generally,
215 the estimates were closer to the SROI AD than HCl. Among the variables that best explained the model
216 (Table 4), AD, *APOE4*, and diabetes medications had the largest effect estimates.
217 Sex and use of diabetic medications had a marginally greater impact on the MCI region than on the AD
218 region. However, race and education were not identified as significant predictors. Infections were

219 associated with a -0.01 reduction in regional metabolism ($p=0.04$). The percentage of variation explained
220 by the model for the SROI MCI was also the highest (28.8%) of the three investigated outcomes.

221 Table 4. Regression estimates for predictors in the reduced multivariate linear regression model for SROI
222 MCI outcome

Variables	Estimates	95% CI	P
AD (Yes)	-0.09	-0.10, -0.08	<0.001 ^{***}
<i>APOE4</i>	-0.02	-0.03, -0.02	<0.001 ^{***}
Age	-0.004	-0.01, -0.003	<0.001 ^{***}
Diabetes Medication (Yes)	-0.04	-0.06, -0.01	0.01 ^{**}
Infections (Yes)	-0.01	-0.03, -0.0005	0.04 [*]
Sex (Male)	-0.02	-0.03, -0.01	<0.001 ^{***}
Smoking (Yes)	-0.01	-0.02, 0.003	0.15

223 Note. ^{*} $p<0.05$; ^{**} $p<0.01$; ^{***} $p<0.001$.

224

225 4 Discussion

226 Results of our study suggest that infections and *APOE4* can jointly significantly affect brain glucose
227 metabolism, specifically promote hypometabolism, as measured by the increased values of HCl. A
228 history of infections in this ADNI sample corresponds to a greater hypometabolism, specifically a 0.15
229 unit increase in rank normalized HCl. However, this estimate rose to 0.44 in the presence of multiple
230 infections. Model inclusion of established confounders such as age, sex, race, and education did not
231 diminish these findings. We also adjusted for AD status, which was more prevalent in the group with no

232 infections and associated with reduced brain metabolism. Adjusting for AD status and *APOE4* was
233 necessary to reveal the genuine association of previous infections. Additionally, previous infections were
234 significantly associated with regional brain metabolism specific to AD and MCI in our data.

235 Our findings agree with previous research suggesting that infections may negatively impact brain
236 metabolism.^{16,41-43} Infectious diseases, including those addressed in this study, have been previously
237 linked to AD in other data.^{22,44-46} Our recent paper that used Health and Retirement Study (HRS) data
238 reported associations between AD and various infectious (viral, bacterial, fungal), suggesting that
239 compromised immunity may play a role in AD etiology.²⁰ The connection between infections and brain
240 hypometabolism may also involve pathological immune responses. Some research provides indirect
241 support to this idea by linking brain hypometabolism to microglia activation.⁴⁷⁻⁴⁹

242 Determining the onset time of infection is a major challenge in AD research. Furthermore, the causal
243 inferences are obscured by the fact that individuals with AD often grapple with a variety of infections
244 due to declining immunity, leading to elevated antimicrobial markers.¹⁶ Pathogens have a high affinity
245 to the central nervous system and brain tissue and could affect cognition.⁵⁰ Given that brain
246 hypometabolism is an early sign of AD, our findings suggest that infections could potentially trigger this
247 process.⁵¹ However, the progression of hypometabolism may also depend upon the combination of
248 other risk factors.⁵² Infections can affect the brain through multiple pathways, both directly and
249 indirectly, particularly when the blood-brain barrier is breached.^{53,54} Infections propagated through the
250 respiratory route can also reach the brain relatively easily.^{50,55} However, upon reaching the brain,
251 different infectious agents employ their preferred mechanisms, such as latent activation and the
252 initiation of inflammation, as seen in the case of the Herpes virus.⁵⁶ Pathogen invasion into the brain
253 leads to chronic inflammation, which can compromise the blood-brain barrier.⁴² There are distinct
254 differences in inflammatory pathways noted across specific pathogens.^{19,57} Age-related changes could
255 exacerbate these pathological processes even further.⁵⁸ Strom and colleagues have also demonstrated

256 that brain hypometabolism correlates with tau pathology and neurodegeneration in crucial dementia-
257 specific regions within the ADNI dataset.⁵⁹ These mechanisms could potentially explain a significant
258 portion of the biological processes leading up to hypometabolism.

259 Studies on the relationship between *APOE4* and brain metabolism have produced contrasting
260 findings.^{59–63} In their recently published work, Fortea and colleagues found that simply being
261 homozygous for *APOE4* is sufficient, in most cases, to guarantee an AD diagnosis.⁶⁴ In our analysis, the
262 increase in *APOE4* allele was associated with all three outcomes and showed compounding effects with
263 infections and their burden. Even in patients with a single *APOE4* variant, which is usually not considered
264 a significant increase in risk compared to homozygous carriers, the presence of infections increases the
265 risk of hypometabolism to nearly the same level as in homozygous *APOE4* carriers. One possibility is that
266 the observed effect is due to accelerated neuroinflammation arising from the presence of both risk
267 factors.⁶⁵ Risk factors for AD tend to cluster in individuals with *APOE* risk alleles, including a reduction in
268 brain metabolism.⁶⁶ Amyloid-beta and Tau deposition are higher in *APOE4* carriers.⁶⁷ *APOE4* can also
269 accelerate brain degeneration through non-overlapping pathways independent of amyloid deposition
270 and Tau pathology.^{68–70} *APOE4* alleles both promote and resist infections, depending on the type of
271 infection.⁷¹ Researchers suggest that *APOE4* polymorphisms result in increased lipid production⁷² and
272 blood-brain barrier loss⁷³, which could facilitate a conducive environment for pathogens.⁷⁴ Supporting
273 evidence from the Northern Manhattan Study showed that the effect-modifying relationship between
274 *APOE4* and infectious burden was correlated with decreased cognition.⁷⁵ The influence of *APOE4* on AD
275 remains incompletely understood, although it is known to engage in intricate interactions with other risk
276 factors for AD, such as age.^{76,77} However, in stark contrast to these findings, a study reported that the
277 effects of *APOE4* on cognition are AD-specific. It singles out the cause of cognitive decline as the
278 interaction between *APOE4* and amyloid beta in the hippocampus.⁷⁸

279 Our study revealed that diabetes medication was the third-biggest risk factor for AD and MCI-specific
280 brain metabolism, but not for the HCl measure. Previous studies indeed demonstrated that diabetes
281 increases the risk for MCI and AD.^{79,80} Individuals with diabetes and AD often share common biological
282 pathways.⁸¹ Most prominent among these are low-grade chronic inflammation and insulin resistance.⁸²

283 Sex differences in mechanisms related to AD warrant in-depth study. Usually, females are susceptible to
284 AD and early brain hypometabolism compared to males.^{83,84} On exposure to prior infections, women are
285 also, particularly at higher risk for reduced hippocampal volume.¹⁹ Males overall had a higher HCl value
286 than females in our sample. It is important to note that males with infections had a slightly higher mean
287 age. But this alone cannot explain the gender difference. Importantly, there was no difference in the
288 increase in marginal means due to infections for both sexes. An earlier study reported that brain
289 hypometabolism increased in men after 70 years of age, while this was not seen in females in a normal
290 brain.⁸⁵ However, the applicability of this finding in the AD context needs confirmation. Some participant
291 characteristics in ADNI may differ from the general population due to voluntary recruitment. Variations
292 in the distribution of AD risk factors among genders might also contribute to this finding.^{86,87}

293 Given that AD is not curable, prevention stands as the most viable option at present. Vaccinations may
294 potentially alleviate dementia risk. Influenza vaccines, in particular, are among the candidates
295 demonstrating this preventive potential.^{4,79} However, personal genetics could play a role in determining
296 the efficacy and effectiveness of vaccinations. Recent research has revealed that individuals carrying a
297 polymorphism in the *NECTIN2* gene exhibit a decreased susceptibility to AD when compared to non-
298 carriers, when receiving vaccinations for pneumonia and flu.²²

299 The availability of medical history information and longitudinally standardized FDG PET measurements
300 were important strengths of our study. We were also able to demonstrate the temporality of
301 association, which was rarely described in earlier human studies.⁸⁸ There were a couple of study

302 limitations. Of these, the most important is that the medical history is questionnaire-based, suggesting
303 that recall bias may exist and lead to an incorrect exposure classification. Currently, the representation of
304 high-risk groups, such as Afro-American and Hispanic individuals, is limited in the ADNI database, which
305 has constrained the evaluation of the effect modification role of race in relation to infections and brain
306 hypometabolism.⁸⁹ In this work, we did not specifically explore the heterogeneity in infections and the
307 brain metabolism relationship. However, previous AD studies indicate that there could be subgroups that
308 may be differentially vulnerable.⁹⁰⁻⁹² There may also be a cohort effect, wherein the frequency of
309 infections observed within this group may not accurately fit the current disease landscape. We
310 recommend validating the findings in large cohorts with robust information on prior infections.

311

312 **5 Conclusion**

313 This study found that infections and *APOE4* jointly promoted brain glucose hypometabolism in older
314 ADNI participants. In individuals with a history of infections who were also carriers of one *APOE4* allele,
315 the degree of brain glucose hypometabolism was nearly that seen in *APOE4* homozygotes without prior
316 infections. We conclude that prior infections may contribute to AD pathology in synergy with *APOE4*,
317 thus playing a part in the “multi-hit” mechanism of AD development.

318

319 **Data Availability**

320 The data used in this manuscript were obtained from the publicly available ADNI database
321 (adni.loni.usc.edu). The ADNI database contains anonymized patient information, making it a secure
322 data repository.

323 **Funding**

324 This research was supported by the National Institutes of Health's National Institute on Aging (NIA/NIH)
325 grants R01AG076019 and R01AG062623. This content is solely the responsibility of the authors and does
326 not necessarily represent the official views of the NIA/NIH.

327

328 **Abbreviations**

AD	Alzheimer's disease
AIC	Akaike Information Criterion
<i>APOE</i>	Apolipoprotein E
A β	Amyloid β
FDG	18F-fluorodeoxyglucose
GxE	Gene-environment interaction
GWAS	Genome-wide association studies
HSV	Herpes Simplex Virus
%INCMSE	Percent Increase in Mean Squared error
IQR	Interquartile Range
PET	Positron Emission Tomography
pTau	Phosphorylated Tau
SD	Standard Deviation
SNP	Single Nucleotide Polymorphism
SROI	Statistical Region of Interest
<i>NECTIN2</i>	Nectin Cell Adhesion Molecule 2 (gene)
PUD	Peptic Ulcer Disease
UTI	Urinary Tract Infection

329

330 **References**

331 1. Tupler L, Yashkin A, Hoque M, Yashin A, Akushevich I, Stallard E. differences in cognitive
332 decline due to Alzheimer’s disease, neurodegenerative disorders, and trauma. *Innov*
333 *Aging*. 2023;7(Suppl 1):852.

334

335 2. 2023 Alzheimer’s disease facts and figures. *Alzheimer’s Dement*. 2023;19:1598–695.

336

337 3. Dubois B, Hampel H, Feldman HH, Scheltens P, Aisen P, Andrieu S, et al. Preclinical
338 Alzheimer’s disease: Definition, natural history, and diagnostic criteria. *Alzheimers*
339 *Dement*. 2016;12(3):323.

340

341 4. Fiandaca MS, Kapogiannis D, Mapstone M, Boxer A, Eitan E, Schwartz JB, et al.
342 Identification of preclinical Alzheimer’s disease by a profile of pathogenic proteins in
343 neurally derived blood exosomes: A case-control study. *Alzheimer’s & Dementia*.
344 2015;11(6):600-607.

345

346 5. Blázquez E, Hurtado-Carneiro V, LeBaut-Ayuso Y, Velázquez E, García-García L, Gómez-
347 Oliver F, et al. Significance of Brain Glucose Hypometabolism, Altered Insulin Signal
348 Transduction, and Insulin Resistance in Several Neurological Diseases. *Front Endocrinol*
349 *(Lausanne)*. 2022;13(873301).

350

351 6. Jack CR, Andrews JS, Beach TG, Buracchio T, Dunn B, Graf A, et al. Revised criteria for
352 diagnosis and staging of Alzheimer's disease. *Nat Med*. 2024;30(8):2121–4.

353

354 7. Atamna H, Frey WH. Mechanisms of mitochondrial dysfunction and energy deficiency in
355 Alzheimer's disease. *Mitochondrion*. 2007;7(5):297–310.

356

357 8. Herholz K. PET studies in dementia. *Ann Nucl Med*. 2003;17(2):79–89.

358

359 9. Mosconi L. Brain glucose metabolism in the early and specific diagnosis of Alzheimer's
360 disease. FDG-PET studies in MCI and AD. *Eur J Nucl Med Mol Imaging*. 2005;32(4):486–
361 510.

362

363 10. Scheltens P, De Strooper B, Kivipelto M, Holstege H, Chételat G, Teunissen CE, et al.
364 Alzheimer's disease. *Lancet*. 2021;397(10284):1590.

365

366 11. Tanzi RE. The Genetics of Alzheimer Disease. *Cold Spring Harb Perspect Med* [Internet].
367 2012;2(10):a006296.

368

- 369 12. Livingston G, Huntley J, Sommerlad A, Ames D, Ballard C, Banerjee S, et al. Dementia
370 prevention, intervention, and care: 2020 report of the Lancet Commission. *Lancet*.
371 2020;396(10248):446.
- 372
- 373 13. De La Torre JC. Alzheimer's disease is incurable but preventable. *J Alzheimers Dis*.
374 2010;20(3):70.
- 375
- 376 14. Grau AJ, Urbanek C, Palm F. Common infections and the risk of stroke. *Nat Rev Neurol*.
377 2010;6:681–94.
- 378
- 379 15. Mcmurry HS, Mendenhall E, Rajendrakumar A, Nambiar L, Satyanarayana S, Shivashankar
380 R. Coprevalence of type 2 diabetes mellitus and tuberculosis in low - income and middle -
381 income countries: A systematic review. *Diabetes Metab Res Rev*. 2019;35(2018).
- 382
- 383 16. Vigasova D, Nemergut M, Liskova B, Damborsky J. Multi-pathogen infections and
384 Alzheimer's disease. *Microb Cell Fact*. 2021;20(25).
- 385
- 386 17. Rippee-Brooks MD, Wu W, Dong J, Pappolla M, Fang X, Bao X. Viral Infections, Are They a
387 Trigger and Risk Factor of Alzheimer's Disease? *Pathogens*. 2024;13(3):240.
- 388

- 389 18. Paranjpe MD, Belonwu S, Wang JK, Oskotsky T, Gupta A, Taubes A, et al. Sex-Specific Cross
390 Tissue Meta-Analysis Identifies Immune Dysregulation in Women With Alzheimer’s
391 Disease. *Front Aging Neurosci.* 2021;13(735611).
- 392
- 393 19. Popov VA, Ukraintseva S, Duan H, Arbeev KG, Yashin AI. Prior infections are associated
394 with smaller hippocampal volume in older women. *Front Dement.* 2024;3(2024).
- 395
- 396 20. Ukraintseva S, Yashkin AP, Akushevich I, Arbeev K, Duan H, Gorbunova G, et al.
397 Associations of infections and vaccines with Alzheimer’s disease point to a role of
398 compromised immunity rather than specific pathogen in AD. *Exp Gerontol.* 2024;190.
- 399
- 400 21. Rajendrakumar L, Ukraintseva S, Arbeev KG, Bagley O, Yashin AI. The association between
401 rs6859 in NECTIN2 gene and Alzheimer’s disease is partly mediated by pTau. *Front Aging*
402 *Neurosci.* 2024;16.
- 403
- 404 22. Ukraintseva S, Duan M, Simanek AM, Holmes R, Bagley O, Rajendrakumar AL, et al.
405 Vaccination Against Pneumonia May Provide Genotype-Specific Protection Against
406 Alzheimer’s Disease. *J Alzheimers Dis.* 2023;96(2):499–505.
- 407

- 408 23. Hosp JA, Dressing A, Blazhenets G, Bormann T, Rau A, Schwabenland M, et al. Cognitive
409 impairment and altered cerebral glucose metabolism in the subacute stage of COVID-19.
410 Brain. 2021;144(4):1263–76.
411
- 412 24. Weber CJ, Carrillo MC, Jagust W, Jack CR, Shaw LM, Trojanowski JQ, et al. The Worldwide
413 Alzheimer’s Disease Neuroimaging Initiative: ADNI-3 updates and global perspectives.
414 Alzheimers Dement (N Y). 2021;7(1):e12226.
415
- 416 25. Ashford MT, Raman R, Miller G, Donohue MC, Okonkwo OC, Mindt MR, et al. Screening
417 and enrollment of underrepresented ethnocultural and educational populations in the
418 Alzheimer’s Disease Neuroimaging Initiative (ADNI). Alzheimer’s Dement. 2022;1–11.
419
- 420 26. Petersen RC, Aisen PS, Beckett LA, Donohue MC, Gamst AC, Harvey DJ, et al. Alzheimer’s
421 Disease Neuroimaging Initiative (ADNI) Clinical characterization. Neurology. 2010;74:201–
422 9.
423
- 424 27. Sudre CH, Cardoso MJ, Frost C, Barnes J, Barkhof F, Fox N, et al. APOE ϵ 4 status is
425 associated with white matter hyperintensities volume accumulation rate independent of
426 AD diagnosis. Neurobiol Aging. 2017;53:67–75.
427

- 428 28. Langbaum JBS, Chen K, Lee W, Reschke C, Bandy D, Fleisher AS, et al. Categorical and
429 correlational analyses of baseline fluorodeoxyglucose positron emission tomography
430 images from the Alzheimer’s Disease Neuroimaging Initiative (ADNI). *Neuroimage*.
431 2009;45(4):1116.
- 432
- 433 29. Jagust WJ, Bandy D, Chen K, Foster NL, Landau SM, Mathis CA, et al. The Alzheimer’s
434 Disease Neuroimaging Initiative positron emission tomography core. *Alzheimer’s &*
435 *Dementia*. 2010;6(3):221–9.
- 436
- 437 30. Mueller SG, Weiner MW, Thal LJ, Petersen RC, Jack C, Jagust W, et al. The Alzheimer’s
438 Disease Neuroimaging Initiative. *Neuroimaging Clin N Am*. 2005;15(4):869-77.
- 439
- 440 31. Chen K, Ayutyanont N, Langbaum JBS, Fleisher AS, Reschke C, Lee W, et al. Characterizing
441 Alzheimer’s disease using a hypometabolic convergence index. *Neuroimage*. 2011;56:52–
442 60.
- 443
- 444 32. Chen K, Langbaum JBS, Fleisher AS, Ayutyanont N, Reschke C, Lee W, et al. Twelve-month
445 metabolic declines in probable Alzheimer’s disease and amnesic mild cognitive
446 impairment assessed using an empirically pre-defined statistical region-of-interest:
447 Findings from the Alzheimer’s Disease Neuroimaging Initiative. *Neuroimage*.
448 2010;51(2):654–64.

- 449
- 450 33. Ewers M, Brendel M, Rizk-Jackson A, Rominger A, Bartenstein P, Schuff N, et al. Reduced
451 FDG-PET brain metabolism and executive function predict clinical progression in elderly
452 healthy subjects. *Neuroimage Clin.* 2014;4:45–52.
- 453
- 454 34. Landau SM, Harvey D, Madison CM, Koeppe RA, Reiman EM, Foster NL, et al. Associations
455 between cognitive, functional, and FDG-PET measures of decline in AD and MCI.
456 *Neurobiol Aging.* 2011:1207–18.
- 457
- 458 35. R Core Team. R: A language and environment for statistical computing. R Foundation for
459 Statistical Computing, Vienna, Austria [Internet]. 2021 [cited 2023 May 15]. Available
460 from: <https://www.R-project.org/>
- 461
- 462 36. Wickham H. *ggplot2: Elegant Graphics for Data Analysis Using the Grammar of Graphics*
463 [Internet]. Springer-Verlag New York; 2016. Available from: <https://ggplot2.tidyverse.org>.
- 464
- 465 37. McCaw Z. RNOmni: Rank Normal Transformation Omnibus Test [Internet]. 2020. Available
466 from: <https://CRAN.R-project.org/package=RNOmni>
- 467
- 468 38. Bartoń K. MuMIn: Multi-model inference [Internet]. Vol. 1, R package version 1.10.0.
469 2013. Available from: <https://cran.r-project.org/web/packages/MuMIn/MuMIn.pdf>

470

471 39. Liaw A, Wiener M. Classification and Regression by randomForest. R News [Internet].
472 2002 [cited 2024 May 2];2(3):18–22. Available from: <http://www.stat.berkeley.edu/>

473

474 40. Johnson PE. Using rockchalk for Regression Analysis * [Internet]. 2017 [cited 2024 Apr 30].
475 Available from: <http://cran.nexr.com/web/packages/rockchalk/vignettes/rockchalk.pdf>

476

477 41. Ashraf GM, Tarasov V V, Makhmutova A, Chubarev VN, Avila-Rodriguez M, Bachurin SO, et
478 al. The Possibility of an Infectious Etiology of Alzheimer Disease. Mol Neurobiol.
479 2019;56:4479–91.

480

481 42. Shinjyo N, Kita K. Infection and Immunometabolism in the Central Nervous System: A
482 Possible Mechanistic Link Between Metabolic Imbalance and Dementia. Front Cell
483 Neurosci. 2021;15(765217).

484

485 43. Butler L, Walker KA. The Role of Chronic Infection in Alzheimer’s Disease: Instigators, Co-
486 conspirators, or Bystanders? Curr Clin Micro Rpt. 2021;8:199–212.

487

488 44. Cairns DM, Itzhaki RF, Kaplan DL. Potential Involvement of Varicella Zoster Virus in
489 Alzheimer’s Disease via Reactivation of Quiescent Herpes Simplex Virus Type 1. J
490 Alzheimers Dis. 2022;88(3):1189–200.

- 491
- 492 45. Bukhbinder AS, Ling Y, Hasan O, Jiang X, Kim Y, Phelps KN, et al. Risk of Alzheimer's
493 Disease Following Influenza Vaccination: A Claims-Based Cohort Study Using Propensity
494 Score Matching. *J Alzheimers Dis.* 2022;88(3):1061–74.
- 495
- 496 46. Noori M, Mahboobi R, Nabavi-Rad A, Jamshidizadeh S, Fakharian F, Yadegar A, et al.
497 *Helicobacter pylori* infection contributes to the expression of Alzheimer's disease-
498 associated risk factors and neuroinflammation. *Heliyon.* 2023;9(9):e19607.
- 499
- 500 47. Tondo G, Boccalini C, Caminiti SP, Presotto L, Filippi M, Magnani G, et al. Brain
501 Metabolism and Microglia Activation in Mild Cognitive Impairment: A Combined [18F]FDG
502 and [11C]-(R)-PK11195 PET Study. *J Alzheimers Dis.* 2021;80(1):433–45.
- 503
- 504 48. Kadamani KL, Logan SM, Pamerter ME. Does hypometabolism constrain innate immune
505 defense? *Acta Physiol.* 2024;240:e14091.
- 506
- 507 49. Aldana BI. Microglia-Specific Metabolic Changes in Neurodegeneration. *J Mol Biol.*
508 2019;431(9):1830–42.
- 509

- 510 50. Guedj E, Million M, Dudouet P, Tissot-Dupont H, Bregeon F, Cammilleri S, et al. 18F-FDG
511 brain PET hypometabolism in post-SARS-CoV-2 infection: substrate for persistent/delayed
512 disorders? *Eur J Nucl Med Mol Imaging*. 2021;48(2):592–5.
513
- 514 51. Zilberter Y, Zilberter M. The vicious circle of hypometabolism in neurodegenerative
515 diseases: Ways and mechanisms of metabolic correction. *J Neurosci Res*. 2017;95:2217–
516 35.
517
- 518 52. Yang Z, Cummings JL, Kinney JW, Cordes D. Accelerated hypometabolism with disease
519 progression associated with faster cognitive decline among amyloid positive patients.
520 *Front Neurosci*. 2023;17.
521
- 522 53. Sweeney MD, Sagare AP, Zlokovic B V. Blood-brain barrier breakdown in Alzheimer
523 disease and other neurodegenerative disorders. *Nat Rev Neurol*. 2018;14(3):133–50.
524
- 525 54. Sochocka M, Zwolińska K, Leszek J. The Infectious Etiology of Alzheimer’s Disease. *Curr*
526 *Neuropharmacol*. 2017;15(7):996–1009.
527
- 528 55. Wan D, Du T, Hong W, Chen L, Que H, Lu S, et al. Neurological complications and infection
529 mechanism of SARS-COV-2. *Signal Transduct Target Ther*. 2021;6(406).
530

- 531 56. Lövheim H, Gilthorpe J, Adolfsson R, Nilsson LG, Elgh F. Reactivated herpes simplex
532 infection increases the risk of Alzheimer's disease. *Alzheimer's & Dementia*.
533 2015;11(6):593–9.
- 534
- 535 57. Chhatbar C, Prinz M. The roles of microglia in viral encephalitis: from sensome to
536 therapeutic targeting. *Cell Mol Immunol*. 2021;18:250–8.
- 537
- 538 58. Montagne A, Barnes SR, Sweeney MD, Halliday MR, Sagare AP, Zhao Z, et al. Blood-brain
539 barrier breakdown in the aging human hippocampus. *Neuron*. 2015;85(2):296–302.
- 540
- 541 59. Strom A, Iaccarino L, Edwards L, Lesman-Segev OH, Soleimani-Meigooni DN, Pham J, et al.
542 Cortical hypometabolism reflects local atrophy and tau pathology in symptomatic
543 Alzheimer's disease. *Brain*. 2022;145(2):713–28.
- 544
- 545 60. Corder EH, Jelic V, Bosun H, Lannfelt L, Valind S, Winblad B, et al. No Difference in
546 Cerebral Glucose Metabolism in Patients With Alzheimer Disease and Differing
547 Apolipoprotein E Genotypes. *Arch Neurol*. 1997;54(3):273–7.
- 548
- 549 61. Rabinovici GD, Furst AJ, Alkalay A, Racine CA, O'Neil JP, Janabi M, et al. Increased
550 metabolic vulnerability in early-onset Alzheimer's disease is not related to amyloid
551 burden. *Brain*. 2010;133(2):512–28.

552

553 62. Lehmann M, Ghosh PM, Madison C, Karydas A, Coppola G, O’Neil JP, et al. Greater medial
554 temporal hypometabolism and lower cortical amyloid burden in ApoE4-positive AD
555 patients. *J Neurol Neurosurg Psychiatry*. 2014;85(3):266–73.

556

557 63. Reiman EM, Caselli RJ, Yun LS, Chen K, Bandy D, Minoshima S, et al. Preclinical Evidence of
558 Alzheimer’s Disease in Persons Homozygous for the ϵ 4 Allele for Apolipoprotein E. *N Engl J*
559 *Med*. 1996;334:752–8.

560

561 64. Fortea J, Pegueroles J, Alcolea D, Belbin O, Dols-Icardo O, Vaqué-Alcázar L, et al. APOE4
562 homozygosity represents a distinct genetic form of Alzheimer’s disease. *Nat Med*.
563 2024;30:1284–91.

564

565 65. Finch CE, Morgan TE. Systemic Inflammation, Infection, ApoE Alleles, and Alzheimer
566 Disease: A Position Paper. *Curr Alzheimer Res*. 2007 ;4(5):185–9.

567

568 66. Duong MT, Nasrallah IM, Wolk DA, Chang CCY, Chang TY. Cholesterol, Atherosclerosis, and
569 APOE in Vascular Contributions to Cognitive Impairment and Dementia (VCID): Potential
570 Mechanisms and Therapy. *Front Aging Neurosci*. 2021;13(647990).

571

- 572 67. Fernández-Calle R, Konings SC, Frontiñán-Rubio J, García-Revilla J, Camprubí-Ferrer L,
573 Svensson M, et al. APOE in the bullseye of neurodegenerative diseases: impact of the
574 APOE genotype in Alzheimer’s disease pathology and brain diseases. Mol
575 Neurodegeneration. 2022;17(62).
- 576
- 577 68. Farmer BC, Williams HC, Devanney NA, Piron MA, Nation GK, Carter DJ, et al. APOE4
578 lowers energy expenditure in females and impairs glucose oxidation by increasing flux
579 through aerobic glycolysis. Mol Neurodegener. 2021;16(1):62.
- 580
- 581 69. Calderón-Garcidueñas L, Hernández-Luna J, Aiello-Mora M, Brito-Aguilar R, Evelson PA,
582 Villarreal-Ríos R, et al. APOE Peripheral and Brain Impact: APOE4 Carriers Accelerate Their
583 Alzheimer Continuum and Have a High Risk of Suicide in PM2.5 Polluted Cities.
584 Biomolecules. 2023;13(6):927.
- 585
- 586 70. Sohn HY, Kim SI, Park JY, Park SH, Koh YH, Kim J, et al. ApoE4 attenuates autophagy via
587 FoxO3a repression in the brain. Sci Rep. 2021;11:17604.
- 588
- 589 71. Chen F, Ke Q, Wei W, Cui L, Wang Y. Apolipoprotein E and viral infection: Risks and
590 Mechanisms. Mol Ther Nucleic Acids. 2023;33:529–42.
- 591

- 592 72. Garcia AR, Finch C, Gatz M, Kraft T, Rodriguez DE, Cummings D, et al. Apoe4 is associated
593 with elevated blood lipids and lower levels of innate immune biomarkers in a tropical
594 amerindian subsistence population. *Elife*. 2021;10:e68231.
- 595
- 596 73. Raulin AC, Doss S V., Trottier ZA, Ikezu TC, Bu G, Liu CC. ApoE in Alzheimer’s disease:
597 pathophysiology and therapeutic strategies. *Mol Neurodegeneration*. 2022;17(72).
- 598
- 599 74. Urosevic N, Martins RN. Infection and Alzheimer’s disease: the APOE epsilon4 connection
600 and lipid metabolism. *J Alzheimers Dis*. 2008;13(4):35.
- 601
- 602 75. Zhao C, Strobino K, Moon YP, Cheung YK, Sacco RL, Stern Y, et al. APOE ε4 modifies the
603 relationship between infectious burden and poor cognition. *Neurol Genet*. 2020;6(4):
604 e462.
- 605
- 606 76. Mosconi L, Herholz K, Prohovnik I, Nacmias B, Cristofaro MTR De, Fayyaz M, et al.
607 Metabolic interaction between ApoE genotype and onset age in Alzheimer’s disease:
608 implications for brain reserve. *Jour*. 2005;76:15–23.
- 609
- 610 77. Khalifa KN. Effect of APOE e4 allele on age-related brain FDG-PET uptake in older
611 individuals at risk of dementia. *Alzheimer’s Dement*. 2023;19:e067424.
- 612

- 613 78. Fernández A, Vaquero L, Bajo R, Zuluaga P, Weiner MW, Saykin AJ, et al. Apolipoprotein E
614 ε4-related effects on cognition are limited to the Alzheimer’s disease spectrum.
615 *Geroscience*. 2022;44:195–209.
- 616
- 617 79. Li W, Risacher SL, Huang E, Saykin AJ. Type 2 diabetes mellitus is associated with brain
618 atrophy and hypometabolism in the ADNI cohort. *Neurology*. 2016;87(6):595–600.
- 619
- 620 80. Raut S, Bhalerao A, Powers M, Gonzalez M, Mancuso S, Cucullo L. Hypometabolism,
621 Alzheimer’s Disease, and Possible Therapeutic Targets: An Overview. *Cells*.
622 2023;12(16):2019.
- 623
- 624 81. De La Monte SM, Wands JR. Alzheimer’s Disease Is Type 3 Diabetes-Evidence Reviewed. *J*
625 *Diabetes Sci Technol*. 2008;2(6):1101–13.
- 626
- 627 82. Jayaraj RL, Azimullah S, Beiram R. Diabetes as a risk factor for Alzheimer’s disease in the
628 Middle East and its shared pathological mediators. *Saudi J Biol Sci*. 2020;27(2):736–50.
- 629
- 630 83. Nebel RA, Aggarwal NT, Barnes LL, Gallagher A, Goldstein JM, Kantarci K, et al.
631 Understanding the impact of sex and gender in Alzheimer’s disease: A call to action.
632 *Alzheimer’s and Dementia*. 2018;14(9):1171–83.

633

- 634 84. Zhao L, Mao Z, Woody SK, Brinton RD. Sex differences in metabolic aging of the brain:
635 insights into female susceptibility to Alzheimer’s disease. *Neurobiol Aging*. 2016;42:69–79.
636
- 637 85. Feng B, Cao J, Yu YP, Yang HY, Jiang YHY, Liu Y, et al. Gender-Related Differences in
638 Regional Cerebral Glucose Metabolism in Normal Aging Brain. *Front Aging Neurosci*.
639 2022;14.
640
- 641 86. Malpetti M, Sala A, Vanoli EG, Gianolli L, Luzi L, Perani D. Unfavourable gender effect of
642 high body mass index on brain metabolism and connectivity. *Sci Rep*. 2018;8:12584.
643
- 644 87. Miller KK, Deckersbach T, Rauch SL, Fischman AJ, Grieco KA, Herzog DB, et al.
645 Testosterone administration attenuates regional brain hypometabolism in women with
646 anorexia nervosa. *Psychiatry Res Neuroimaging*. 2004;132(3):197–207.
647
- 648 88. Muzambi R, Bhaskaran K, Brayne C, Davidson JA, Smeeth L, Warren-Gash C. Common
649 Bacterial Infections and Risk of Dementia or Cognitive Decline: A Systematic Review. *J*
650 *Alzheimer’s Dis*. 2020;76(4):1626.
651
- 652 89. Lim AC, Barnes LL, Weissberger GH, Lamar M, Nguyen AL, Fenton L, et al. Quantification of
653 race/ethnicity representation in Alzheimer’s disease neuroimaging research in the USA: a
654 systematic review. *Commun Med*. 2023;3(101).

655

656 90. Veitch DP, Weiner MW, Aisen PS, Beckett LA, DeCarli C, Green RC, et al. Using the
657 Alzheimer's Disease Neuroimaging Initiative to improve early detection, diagnosis, and
658 treatment of Alzheimer's disease. *Alzheimer's & Dementia*. 2022;18(4):824–57.

659

660 91. Phillips JS, Das SR, McMillan CT, Irwin DJ, Roll EE, Da Re F, et al. Tau PET imaging predicts
661 cognition in atypical variants of Alzheimer's disease. *Hum Brain Mapp*. 2018;39(2):691–
662 708.

663

664 92. Sun N, Mormino EC, Chen J, Sabuncu MR, Yeo BTT. Multi-modal latent factor exploration
665 of atrophy, cognitive and tau heterogeneity in Alzheimer's disease. *Neuroimage*.
666 2019;201(116043).

667

668 **Acknowledgements**

669 Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging
670 Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of
671 Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the
672 National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from
673 the following: AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech;
674 BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan
675 Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated
676 company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy

677 Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.;
678 Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack
679 Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda
680 Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is
681 providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by
682 the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the
683 Northern California Institute for Research and Education, and the study is coordinated by the
684 Alzheimer's Therapeutic Research Institute at the University of Southern California. ADNI data are
685 disseminated by the Laboratory for Neuro Imaging at the University of Southern California.

686 **Consent for publication**

687 Not applicable

688

689 **Funding**

690 This research was supported by the National Institute on Aging of the National Institutes of Health under
691 Award Numbers R01AG076019 and R01AG062623. The content is solely the responsibility of the authors
692 and does not necessarily represent the official views of the National Institutes of Health.

693

694 **Author Information**

695 **Authors and Affiliations**

696 ¹*Biodemography of Aging Research Unit, Social Science Research Institute, Duke University, Durham, NC,*
697 *27708-0408, USA.*

698

699 **Contributions**

700 S.U., K.G.A., A.I.Y., and A.L.R. were involved in the hypothesis generation, study design, and study
701 supervision, and they critically revised the manuscript. A.L.R., M.D., and O.B. were responsible for data
702 cleaning. A.L.R. contributed to the analysis, interpretation of the data, and manuscript writing. All
703 authors read and approved the submitted version of the manuscript.

704

705 **Corresponding Author Information**

706 ^{\$\$}Correspondence to ALR and SU, Email address: alr75@duke.edu, Svetlana.Ukraintseva@duke.edu

707

708 **Competing Interests**

709 The authors declare no competing interests.

710

711 **Additional Information**

712 Supplementary File 1

713 Supplementary File 2

714

715

716